Login
$IRD
$4.10 +$0.06 (1.49%) After hours

$IRD 8-K/A SEC Filings

Filed On Filing
07 Jan 2025 8-K/A: Financial Statements and Exhibits

We have audited the financial statements of Opus Genetics, Inc. (the Company), which comprise the balance sheet as of December 31, 2023, and the related statements of operations and comprehensive loss, changes in convertible preferred st...

07 Jun 2021 8-K/A: Entry into a Material Definitive Agreement; Other Events

PURCHASE AGREEMENT (this “Agreement”), dated as of June 4, 2021, by and among OCUPHIRE PHARMA, INC., a Delaware corporation (the “Company”), and the investors identified on Schedule I hereto (each, an “Investor” and collectively, the “In...

30 Dec 2020 8-K/A: Financial Statements and Exhibits

Ocuphire Pharma, Inc. (Ocuphire or the Company) was incorporated as a C-corporation in the state of Delaware on February 21, 2018. On April 9, 2018, Ocularis Pharma, LLC, a Delaware limited liability company (LLC), and Ocularis Pharma, I...

02 Mar 2009 8-K/A: Changes in Registrant's Certifying Accountant

We are the former independent registered public accounting firm for Rexahn Pharmaceuticals, (the "Company"). We have read the Company's disclosure set forth in Item 4.01 "Changes in Registrant's Certifying Accountant" of the Company's Cu...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support